Flamingo Therapeutics develops RNA-targeted therapies that specifically modulate undruggable transcription factors and splice variants associated with various cancer types. Their discovery engine utilizes advanced antisense chemistry to identify and target RNA elements, addressing significant gaps in treatment options for patients with difficult-to-treat cancers.
Funding
$5.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AIFounders
Product
Problem
Many cancers rely on specific transcription factors and splice variants for their growth and survival, but these RNA targets have historically been difficult to address with conventional drug modalities. This leaves a significant unmet need for patients with cancers that are driven by these "undruggable" targets.
Solution
Flamingo Therapeutics is developing a new class of RNA-targeted therapies designed to selectively modulate key transcription factors and splice variants implicated in cancer. Their approach leverages advanced antisense chemistry to identify and bind to specific RNA elements, thereby disrupting the expression of disease-driving proteins. By targeting these previously inaccessible nodes, Flamingo aims to provide novel treatment options for patients with cancers that have proven resistant to existing therapies. Their late-stage pipeline focuses on delivering therapeutic benefit to patients living with cancer.
Target Audience
The primary target audience includes patients with cancer, particularly those with limited treatment options due to the involvement of traditionally "undruggable" RNA targets, and the clinicians who treat them.
Features
- Antisense oligonucleotide (ASO) platform for selective RNA targeting
- Focus on "undruggable" transcription factors and splice variants
- Advanced antisense chemistry for enhanced target affinity and specificity
- Development of therapies for difficult-to-treat cancers